Forma Therapeutics Holdings, Inc. (FMTX) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	S-1
Revenues	0.0	0.0	100.6	164.1
Revenue growth		-100.0%	-38.7%
Cost of goods sold	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	100.6	164.1
Gross margin			100.0%	100.0%
Selling, general and administrative [+]	174.0	124.2	24.4	21.5
General and administrative			24.4	21.5
Research and development			111.3	132.9
Other operating expenses	-1.1	-29.3
EBITDA [+]	-171.4	-93.6	-32.5	13.2
EBITDA growth	83.1%	188.1%	-345.8%
EBITDA margin			-32.3%	8.1%
Depreciation and amortization	1.6	1.3	2.7	3.5
EBIT [+]	-172.9	-94.9	-35.2	9.7
EBIT growth	82.3%	169.8%	-462.8%
EBIT margin			-35.0%	5.9%
Non-recurring items			5.3
Interest income	1.1	3.4	2.9	3.7
Interest income	1.1	3.4	2.9	3.7
Other income (expense), net [+]	-0.9	-8.7	1.0	0.5
Change in fair value of warrants		2.6	-1.0	-0.5
Other non-operating gains/losses	0.1	-2.7	1.0	0.5
Other	0.1	-2.7	1.0	0.5
Pre-tax income	-172.8	-100.1	-36.6	13.9
Income taxes	0.2	-29.7	-1.8	8.6
Tax rate		29.7%	5.0%	61.8%
Net income	-173.0	-70.4	-52.7	0.1
Net margin			-52.5%	0.1%

Basic EPS [+]	($3.65)	($3.05)	($20.70)	$0.04
Growth	19.6%	-85.2%	-56817.1%
Diluted EPS [+]	($3.65)	($3.05)	($20.70)	$0.04
Growth	19.6%	-85.2%	-58124.4%

Shares outstanding (basic) [+]	47.3	23.1	2.5	2.5
Growth	105.3%	804.9%	0.0%
Shares outstanding (diluted) [+]	47.3	23.1	2.5	2.6
Growth	105.3%	804.9%	-2.3%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.